Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab + Chemotherapy in SCCHN
NCT00460265Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2007
- Primary completion
- May 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 3, randomised, open-label trial of panitumumab in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by Amgen. Primary endpoint: Overall Survival at 56 months. Started May 2007; status: completed.
02
Drugs
panitumumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00460265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00460265.